Gilead Sciences (NASDAQ:GILD) Insider Sells $3,676,120.00 in Stock

Gilead Sciences, Inc. (NASDAQ:GILD) insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the completion of the sale, the insider directly owned 125,779 shares in the company, valued at approximately $16,513,524.91. This represents a 18.21% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Johanna Mercier also recently made the following trade(s):

• On Wednesday, April 15th, Johanna Mercier sold 3,000 shares of Gilead Sciences stock. The stock was sold at an average price of $140.96, for a total transaction of $422,880.00.
• On Monday, March 16th, Johanna Mercier sold 3,000 shares of Gilead Sciences stock. The stock was sold at an average price of $144.23, for a total transaction of $432,690.00.
• On Tuesday, February 17th, Johanna Mercier sold 28,000 shares of Gilead Sciences stock. The stock was sold at an average price of $154.44, for a total transaction of $4,324,320.00.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $130.69 on Thursday. The company’s fifty day simple moving average is $136.86 and its 200-day simple moving average is $133.57. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89. The firm has a market cap of $162.26 billion, a PE ratio of 17.81 and a beta of 0.31. Gilead Sciences, Inc. has a 12 month low of $104.46 and a 12 month high of $157.29.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. The business had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.81 earnings per share. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Equities research analysts expect that Gilead Sciences, Inc. will post -0.77 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be given a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date of this dividend is Monday, June 15th. Gilead Sciences’s payout ratio is currently 44.69%.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on GILD. Barclays began coverage on shares of Gilead Sciences in a report on Friday, February 20th. They set an “equal weight” rating and a $155.00 target price on the stock. Argus boosted their target price on shares of Gilead Sciences from $135.00 to $165.00 and gave the stock a “buy” rating in a report on Thursday, February 19th. Oppenheimer boosted their target price on shares of Gilead Sciences from $128.00 to $165.00 and gave the stock an “outperform” rating in a report on Wednesday, February 11th. Sanford C. Bernstein restated an “outperform” rating and set a $160.00 target price on shares of Gilead Sciences in a report on Wednesday, February 11th. Finally, Leerink Partners lowered their target price on shares of Gilead Sciences from $148.00 to $146.00 in a report on Friday, May 8th. Twenty-five research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $156.93.

Institutional Investors Weigh In On Gilead Sciences

A number of institutional investors have recently modified their holdings of the business. Csenge Advisory Group lifted its position in Gilead Sciences by 319.0% in the 3rd quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company’s stock worth $2,375,000 after buying an additional 16,288 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its position in Gilead Sciences by 52.1% in the 3rd quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 78,494 shares of the biopharmaceutical company’s stock worth $8,713,000 after buying an additional 26,882 shares during the last quarter. Cookson Peirce & Co. Inc. lifted its position in Gilead Sciences by 249.1% in the 3rd quarter. Cookson Peirce & Co. Inc. now owns 10,045 shares of the biopharmaceutical company’s stock worth $1,115,000 after buying an additional 7,168 shares during the last quarter. iA Global Asset Management Inc. lifted its position in Gilead Sciences by 11.6% in the 3rd quarter. iA Global Asset Management Inc. now owns 221,890 shares of the biopharmaceutical company’s stock worth $24,630,000 after buying an additional 23,046 shares during the last quarter. Finally, Sector Gamma AS lifted its position in Gilead Sciences by 15.9% in the 3rd quarter. Sector Gamma AS now owns 147,239 shares of the biopharmaceutical company’s stock worth $16,344,000 after buying an additional 20,239 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Maxim Group upgraded Gilead Sciences (GILD) from hold to buy and set a $165 price target, signaling meaningful upside from current levels. Benzinga report on Maxim Group upgrade
• Positive Sentiment: Gilead announced a quarterly dividend of $0.82 per share, reinforcing its appeal as a cash-generating, income-producing biotech with a 2.5% annualized yield.
• Neutral Sentiment: Gilead launched a new $3 billion senior notes offering, which boosts balance-sheet flexibility but also adds to debt financing activity that investors may watch closely. TipRanks article on senior notes
• Neutral Sentiment: Zacks noted that GILD is drawing unusual investor attention, but the item did not include a fresh fundamental catalyst. Zacks trending stock article
• Negative Sentiment: Daiwa Securities trimmed its price target on Gilead to $150 from $161, suggesting some moderation in analyst expectations despite maintaining an outperform rating. MarketScreener report on Daiwa target cut
• Negative Sentiment: Recent insider selling by senior executives, including the CFO, may create a small overhang for sentiment, even though the trades were pre-planned. InsiderTrades report on CFO sale

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.